Amgen
Biotech company creating biologic medicines
CRM Software Engineer - Information Systems
About the job
- A doctorate degree, or a master's degree with 6–11 years of experience, a bachelor's degree with 8–13 years of experience, or a diploma with 10–15 years of experience in Computer Science, Information Technology, or a related field is required.
- At least 5 years of experience as a Salesforce CRM Developer is required.
- In-depth knowledge of Salesforce development, including experience with MuleSoft or Databricks integrations, is required.
- Hands-on experience with the Salesforce security model, including organization-wide defaults, sharing rules, profiles, and permissions, is required.
- Experience with version control systems such as Git is required.
- Salesforce Developer 2 certification is required.
- Lead development in Salesforce and Veeva CRM to build and configure new and existing features.
- Collaborate with Product Owners and cross-functional development teams to plan and schedule releases, providing guidance on release dependencies, technical constraints, and risks.
- Support development teams in automating build, test, and deployment processes to enable continuous integration and continuous delivery in the Salesforce and Veeva ecosystem.
- Provide ongoing support and troubleshooting for post-release issues, ensuring timely resolution.
- Maintain and optimize existing configurations and customizations by limiting or eliminating technical debt.
- Partner with development teams to apply agile software delivery and DevOps practices within the continuous integration and continuous delivery pipeline.
- Research Veeva and Salesforce capabilities to meet business requirements and provide gap analysis.
- Collaborate with developers, Product Owners, Business Analysts, Salesforce Administrators, quality assurance analysts, Scrum Masters, and cross-functional teams.
- Develop innovative solutions using generative artificial intelligence technologies.
- Conduct code reviews to ensure code quality and adherence to best practices.
- Create and maintain documentation covering software architecture, design, deployment, disaster recovery, and operations.
- Design, develop, and implement applications and modules, including custom reports, interfaces, and enhancements.
- Analyze functional and technical requirements and translate them into software architecture and design specifications.
- Develop and execute unit tests, integration tests, and other testing strategies to ensure software quality.
- Identify and resolve software bugs and performance issues.
- Maintain detailed documentation of software designs, code, and development processes.
- Drive production support for the CRM platform to ensure efficient service to system users.
- Experience working with Veeva CRM and large CRM migrations.
- Proficiency in Apex, JavaScript, and other programming languages.
- Experience developing and managing Salesforce continuous integration and continuous delivery pipelines using SFDX, ANT, or packaged solutions such as Copado.
- Strong understanding of continuous integration and continuous delivery concepts, integration methodologies, and relevant technologies.
- Experience integrating off-platform solutions, such as testing platforms and code-scanning tools, with continuous integration and continuous delivery pipelines.
- Salesforce Development Lifecycle Designer certification.
- Salesforce Platform Builder certification.
- Veeva CRM Systems Administrator certification.
- Copado Fundamentals I or II certification for administrators or developers.
About the company
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 9% to $10.1 billion, with six growth drugs up 26%.
- Repatha sales jumped 37% in Q2 2026, and Medicare-access expansion broadens prescriptions.
- MariTide entered nine Phase 3 studies in 2026, targeting obesity, diabetes, sleep apnea, and cardiovascular disease.
What critics are saying
- Bristol Myers and Ono sued Amgen on Sept. 15, 2026, over Opdivo biosimilar patents.
- Britain suspended Tavneos for new patients in September 2026 after calling supporting data unreliable.
- Prolia and XGEVA biosimilar pressure already cut Q2 2026 sales 33%, and MariTide is unproven.
What makes Amgen unique
- Amgen’s Aug. 2026 pipeline spans Repatha, IMDELLTRA, MariTide, and olpasiran simultaneously.
- Repatha holds primary- and secondary-prevention outcomes data, uncommon among PCSK9 competitors.
- IMDELLTRA became an August 2026 growth engine, reaching $288 million quarterly sales.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.
Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.
Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.